Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280599019> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4280599019 endingPage "604" @default.
- W4280599019 startingPage "603.2" @default.
- W4280599019 abstract "Drugs targeting the orphan receptor GPR35 have potential therapeutic application in a number of disease areas, including inflammation, metabolic disorders, nociception, and cardiovascular disease. Currently available surrogate GPR35 agonists identified from pharmacologically relevant compound libraries have limited utility due to the likelihood of off-target effects in vitro and in vivo and the variable potency that such ligands exhibit across species. We sought to identify and characterize novel GPR35 agonists to facilitate studies aimed at defining the physiologic role of GPR35. PathHunter <i>β</i>-arrestin recruitment technology was validated as a human GPR35 screening assay, and a high-throughput screen of 100,000 diverse low molecular weight compounds was conducted. Confirmed GPR35 agonists from five distinct chemotypes were selected for detailed characterization using both <i>β</i>-arrestin recruitment and G protein-dependent assays and each of the human, mouse, and rat GPR35 orthologs. These studies identified 4-{(Z)-[(2Z)-2-(2-fluorobenzylidene)-4-oxo-1,3-thiazolidin-5-ylidene]methyl}benzoic acid (compound 1) as the highest potency full agonist of human GPR35 yet described. As with certain other GPR35 agonists, compound 1 was markedly selective for human GPR35, but displayed elements of signal bias between <i>β</i>-arrestin-2 and G protein-dependent assays. Compound 1 also displayed competitive behavior when assessed against the human GPR35 antagonist, ML-145 (2-hydroxy-4-[4-(5<i>Z</i>)-5-[(<i>E</i>)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid). Of the other chemotypes studied, compounds 2 and 3 were selective for the human receptor, but compounds 4 and 5 demonstrated similar activity at human, rat, and mouse GPR35 orthologs. Further characterization of these compounds and related analogs is likely to facilitate a better understanding of GPR35 in health and disease." @default.
- W4280599019 created "2022-05-22" @default.
- W4280599019 creator A5009097451 @default.
- W4280599019 creator A5025156152 @default.
- W4280599019 creator A5055359298 @default.
- W4280599019 creator A5083360613 @default.
- W4280599019 date "2022-05-09" @default.
- W4280599019 modified "2023-09-29" @default.
- W4280599019 title "Over-the-scope clips versus standard treatment" @default.
- W4280599019 cites W1874038071 @default.
- W4280599019 cites W2803619919 @default.
- W4280599019 cites W2803962350 @default.
- W4280599019 cites W3015066528 @default.
- W4280599019 cites W3063495048 @default.
- W4280599019 cites W3157215120 @default.
- W4280599019 cites W3172933970 @default.
- W4280599019 cites W4200139316 @default.
- W4280599019 cites W4220931412 @default.
- W4280599019 doi "https://doi.org/10.1136/gutjnl-2022-327712" @default.
- W4280599019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35534090" @default.
- W4280599019 hasPublicationYear "2022" @default.
- W4280599019 type Work @default.
- W4280599019 citedByCount "2" @default.
- W4280599019 countsByYear W42805990192022 @default.
- W4280599019 countsByYear W42805990192023 @default.
- W4280599019 crossrefType "journal-article" @default.
- W4280599019 hasAuthorship W4280599019A5009097451 @default.
- W4280599019 hasAuthorship W4280599019A5025156152 @default.
- W4280599019 hasAuthorship W4280599019A5055359298 @default.
- W4280599019 hasAuthorship W4280599019A5083360613 @default.
- W4280599019 hasConcept C150903083 @default.
- W4280599019 hasConcept C170493617 @default.
- W4280599019 hasConcept C185592680 @default.
- W4280599019 hasConcept C202751555 @default.
- W4280599019 hasConcept C207001950 @default.
- W4280599019 hasConcept C2778938600 @default.
- W4280599019 hasConcept C55493867 @default.
- W4280599019 hasConcept C57992300 @default.
- W4280599019 hasConcept C86803240 @default.
- W4280599019 hasConcept C98274493 @default.
- W4280599019 hasConceptScore W4280599019C150903083 @default.
- W4280599019 hasConceptScore W4280599019C170493617 @default.
- W4280599019 hasConceptScore W4280599019C185592680 @default.
- W4280599019 hasConceptScore W4280599019C202751555 @default.
- W4280599019 hasConceptScore W4280599019C207001950 @default.
- W4280599019 hasConceptScore W4280599019C2778938600 @default.
- W4280599019 hasConceptScore W4280599019C55493867 @default.
- W4280599019 hasConceptScore W4280599019C57992300 @default.
- W4280599019 hasConceptScore W4280599019C86803240 @default.
- W4280599019 hasConceptScore W4280599019C98274493 @default.
- W4280599019 hasIssue "3" @default.
- W4280599019 hasLocation W42805990191 @default.
- W4280599019 hasLocation W42805990192 @default.
- W4280599019 hasOpenAccess W4280599019 @default.
- W4280599019 hasPrimaryLocation W42805990191 @default.
- W4280599019 hasRelatedWork W2019700826 @default.
- W4280599019 hasRelatedWork W2067960249 @default.
- W4280599019 hasRelatedWork W2113533503 @default.
- W4280599019 hasRelatedWork W2119697230 @default.
- W4280599019 hasRelatedWork W2134417758 @default.
- W4280599019 hasRelatedWork W2145306431 @default.
- W4280599019 hasRelatedWork W2297634741 @default.
- W4280599019 hasRelatedWork W2396932951 @default.
- W4280599019 hasRelatedWork W2800648910 @default.
- W4280599019 hasRelatedWork W2953758866 @default.
- W4280599019 hasVolume "72" @default.
- W4280599019 isParatext "false" @default.
- W4280599019 isRetracted "false" @default.
- W4280599019 workType "article" @default.